Results 211 to 220 of about 92,350 (272)

Breakthrough Hemolysis in Paroxysmal Nocturnal Hemoglobinuria: Mechanistic Insights and Management Strategies

open access: yesTransfusion, Volume 66, Issue 11, Page 2421-2431, November 2026.
Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder caused by somatic mutations in the PIGA gene, resulting in loss of glycosylphosphatidylinositol (GPI)‐anchored proteins, including the complement regulatory proteins, CD55 and CD59.
Ganesh Raman   +4 more
wiley   +1 more source

An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres

open access: yesMedical Journal of Australia, Volume 224, Issue 11, November 2026.
ABSTRACT Adoptive cellular therapies (ACT), including tumour‐infiltrating lymphocyte (TIL), T‐cell receptor‐engineered T (TCR‐T) cell and chimeric antigen receptor T‐cell (CAR‐T) therapies, represent an evolving class of immunotherapies with established efficacy in selected haematological malignancies and emerging applications in solid tumours ...
Sarah Childs   +15 more
wiley   +1 more source

Case Report: Refractory childhood-onset takayasu arteritis with digital clubbing and extensive supra-aortic and lower-limb arterial disease. [PDF]

open access: yesFront Pediatr
Abunejma FM   +9 more
europepmc   +1 more source

Comparative Protective Effects of Anakinra and Tocilizumab in Experimental Ocular Ischemic Syndrome. [PDF]

open access: yesInt J Mol Sci
Karimov S   +8 more
europepmc   +1 more source

Author Correction: Tocilizumab versus sarilumab among adults hospitalised with COVID-19: target trial emulation across England and Scotland. [PDF]

open access: yesNat Commun
Zheng B   +16 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy